Venetoclax Shows Promise as Salvage Therapy in CLL

Venetoclax (Venclexta) induced a response in two-thirds of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had progressed after receiving prior therapy with idelalisib (Zydelig), according to findings of a phase II study recently published in Blood.

Venetoclax was associated with a 67% investigator-assessed overall response rate (ORR) among patients who had received prior idelalisib (n = 36).